Hyperion Therapeutics
Closed- Headquarters
- South San Francisco, California
- Employees
- 51–200
- Founded
- 2006
- Business Model
- B2B
- Total Funding
- $117.5M
- Last Round
- $17.5M Venture RoundApr 2011
- Rounds
- 4
About
Hyperion Therapeutics was a Brisbane, CA-based commercial-stage biopharmaceutical company founded in 2006, focused on orphan diseases. The company developed and commercialized RAVICTI (glycerol phenylbutyrate) and BUPHENYL for urea cycle disorders. Hyperion went public on Nasdaq before being acquired by Horizon Pharma in May 2015 for approximately $1.1 billion.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
May 2015
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biotechnology company focused on developing and commercializing innovative, empowered monoclonal ...
Biotechnology company focused on the development of antibody-drug conjugates for the treatment of...
Clinical-stage biotech developing innovative sustained-release therapeutics for serious retinal d...
Biotechnology company developing new medicines to treat rare disorders of calcification with init...
Clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases, ...
Azenta Life Sciences provides automated sample management, storage solutions, and genomics servic...